Mechanisms of Resistance to Antibody-Drug Conjugates

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Antibody-drug conjugates (ADCs) deliver cytotoxic payloads to cancer cells, offering targeted therapy with reduced side effects.
• ADCs are approved for HER2+, triple-negative (TNBC), and hormone receptor-positive (HR+) breast cancers.
• Despite initial success, acquired resistance necessitates understanding and overcoming treatment limitations.

Purpose of the Study:

• To review and categorize the mechanisms of acquired resistance to antibody-drug conjugates (ADCs).
• To explore potential strategies for overcoming ADC resistance in cancer treatment.
• To identify future directions for enhancing ADC efficacy and expanding therapeutic applications.

Main Methods:

• Literature review of recently published studies on ADC resistance.
• Categorization of resistance mechanisms into antigen expression changes, ADC processing/resistance, and payload efflux.
• Analysis of potential therapeutic strategies to circumvent identified resistance pathways.

Main Results:

• Key resistance mechanisms include altered antigen expression, impaired ADC processing, and increased payload efflux.
• These mechanisms can develop individually or in combination, leading to treatment failure.
• Emerging strategies aim to target these resistance pathways to restore ADC sensitivity.

Conclusions:

• Understanding ADC resistance mechanisms is crucial for developing next-line therapies.
• Strategies to overcome resistance may involve combination therapies or novel drug designs.
• Further research is needed to optimize ADC use and improve long-term patient survival.